ObjectiveTo analyze the clinical effects and adverse reactions of oxycodone sustained-release tablet combined with zoledronic acid in the treatment of malignant tumor bone metastasis pain.

MethodsSixty-four patients with malignant tumor complicated with bone metastasis pain were selected.The patients treated with oxycodone sustained-release tablet combined with zoledronic acid and oxycodone sustained-release tablet were divided into the observation group and control group, respectively.The dosage of oxycodone sustained-release tablet, adverse reaction, pain score and quality of life in two groups were retrospectively analyzed.

ResultsThere was no statistical significance in the dosage of oxycodone sustained-release tablet, quality of life and NRS score between two groups after the first titration(P>0.05).The differences of the dose of oxycodone sustained-release tablet after two weeks of treatment, and quality of life after four weeks of treatment between two groups were statistically significant(P < 0.05), and the difference of the NRS score between two groups was not statistically significant(P>0.05).The differences of the adverse reactions, which included constipation, nausea, vomiting, lethargy, urinary retention, paralysis and cognitive impairment, were statistically significant between two groups(P < 0.05).

ConclusionsZoledronic acid in treating bone metastasis cancer pain can reduce the dosage of oxycodone sustained-release tablet, improve the quality of life, and reduce the incidence rate of adverse reactions.